Health Care Delivery

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

The authors suggest their data could reflect phlebotomy’s role as a reactive rather than sustained control measure.

Moderna’s mRNA flu vaccine receives FDA approval after phase 3 data showed improved efficacy compared with standard flu vaccines.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

Nearly 60% of medical health plans, 50% of dental health plans, and 25% of providers reported using AI within their workflows in 2025, with use concentrated in administrative functions.

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

Experts discuss barriers to eating disorder diagnosis and treatment for BIPOC patients and strategies to improve equitable care.